Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com


The Oncomap™test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. Using next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the test identifies actionable genomic alterations within 3-5 business days and with small tissue sample sizes.1 The test guides timely discussions and decisions, while helping physicians understand a patient’s tumor profile to recommend targeted therapies or clinical trials.


1Internal Data on File. Exact Sciences Corporation. Madison, WI. Turnaround time based on qualified sample receipt.